Investor Ideas #Potcasts,
#Cannabis News and #Stocks on the Move; Episode 486 (CSE: $PILL.C) (OTCQB: $CTABF)
(NASDAQ: $NEPT) (TSX: $NEPT.TO) (CSE: $BEV.C) (OTCQB: $BVNNF)
Today's podcast sponsored by Cannabis Suisse Corp.
(OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in
Switzerland
Delta, Kelowna, BC, October 27, 2020 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site,
www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/102720-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10271PILL-CTABF-NEPT-BEV-BVNNF.asp
Hear the investor ideas potcast on
Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing
yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
In
today’s podcast we look at a few public and private company announcements.
Canntab
Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) announced the impending launch of its suite of
hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. (ASX: CGB).
CANN Global through its management
partnership with Medcan Australia Pty Ltd,
received an import permit and have placed an initial order for Canntab's
products. Canntab will immediately apply for an export permit with Health
Canada, which will allow it to fulfill this purchase order. The Company intends
to ship its suite of Patented and Patent Pending products, including THC, CBD
and THC/CBD combination hard pill formulations to CANN Global before the end of
2020. Once the products are shipped to CANN Global in Australia, the products
will be distributed throughout Australia to
medical distributors, including Doctors, Pharmacies, and Hospitals.
Applied Cannabis Research
("ACR"), a leading Australian contract research organization focused
exclusively on medical cannabis treatments, has launched Australia's largest
observational study ever undertaken for medical cannabis. Canntab, through the
products it supplies to CANN Global Ltd., which is a direct participant in the
study, will be participating in this clinical collaboration with major
Australian clinics and hospitals to complete the Cannabinoid Medicine
Observational Study ("CMOS") that will collect data from 20,000
patients nationwide over 5 years. CMOS aims to assess the safety and efficacy
of medicinal cannabis products for a range of refractory conditions including
fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health
and neurological conditions using cannabis, including Canntab's Hard Pill
Cannabinoid Formulations. ACR will lead the study in conjunction with
Australia's medical community and key industry partners such as Althea Group
Holdings , Cronos Australia , Cymra Life Sciences , Medcan Australia and Cann
Global.
"This deal is two years in the
making and represents important milestones for our company," explains
Larry Latowsky, Chief Executive Officer of Canntab. Mr. Latowsky continues,
"it is the first of what will be many international alliances and
agreements to export our patented products for distribution through our
partners' networks, and it is the first observational clinical study that we are
confident will support our vision of our product as unique, effective and the
preferred cannabinoid delivery system for many medical symptoms and
conditions."
Sholom Feldman, CANN Global's
Managing Director says: "We are very excited to progress the launch of Canntab's
innovative cannabis-based tablets in Australia which we expect will be very
sought-after by Doctors who are looking to prescribe pharmaceutical grade
medicinal Cannabis products to their patients. It is our understanding from
discussions with medical professionals that it is easier for them to prescribe
a uniform dosage tablet produced to pharmaceutical grade standards compared to
unreliability of delivery methods used by other products already on the market,
giving our product a solid competitive advantage."
The legal cannabis market is
expected to be worth US$1.55 billion by 2024 in Australia, New Zealand and the
surrounding islands, with medicinal cannabis accounting for approximately 40%
of the market.
Australia is expected to account for
79% of the region's overall market by 2024, due to a comparably larger
population and higher household disposable income than New Zealand and the
islands across the region.
BevCanna
Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) announced that it has successfully completed
the R&D and trial production runs of its exclusively licenced award winning
line of Keef Beverages and the white-label beverages the Company is producing
for State B Beverages.
BevCanna
produced and evaluated multiple formulations of the Keef and State B products,
including sparkling water, tea-based and soda formats, and multiple bottling
formats, including PET and aluminum. Tests were conducted for research and
development, shelf stability testing and equipment commissioning purposes, in
preparation for the receipt of their Standard Processing License and subsequent
product commercialization by Q1 2021.
BevCanna
is currently in late-stage discussions to partner with a leading Canadian
Licensed Producer ("LP") to distribute its products to provincial
cannabis distribution boards through the LP's Health Canada issued Sales
License. This will allow BevCanna to begin distribution of its white-label
client products, Keef & Cali-Bloom branded products and its own branded
products across Canada in Q1 2021, bridging the gap until the Company receives
its own Sales License, expected in 2021.
"The
inaugural production runs of Keef and State B were extremely successful and
we're now moving full steam ahead with our product testing and quality
assurance programs," said John Campbell. "We're particularly excited
to take the next step with our own branded and exclusively licensed product
commercialization efforts, in tandem with our white label partners. We'll be
fully prepared to move ahead with production once we receive our Standard
Processing License."
BevCanna
owns and operates one of the highest-capacity cannabis beverage processing and
packaging facilities in Canada and holds the exclusive rights to a pristine
spring water aquifer, achieving a bottling capacity of up to 210 million
bottles per year. The specialized facility was purpose-built to manufacture
BevCanna's infused house brands and those of BevCanna white-label clients
launching cannabis 2.0 products. BevCanna's service model allows both
cannabis-license holders and non-licensed CPG groups seeking to enter the
Canadian cannabis market.
BevCanna's
state of the art facility currently is capable of formulating, processing and
packaging a range of beverage product formats, including carbonated and
non-carbonated aluminum canned and PET beverages. The new beverages will be
offered in a variety of sizes, ranging from 60ml-1L, in both standard form and
custom vessels.
Neptune
Wellness Solutions, Inc. (NASDAQ: NEPT) (TSX: NEPT) announced entering into a supply agreement
with the Ontario Cannabis Store (OCS), the wholesaler and sole online retailer
for recreational cannabis, for the sale and distribution of Neptune's new
proprietary recreational product line, Mood Ring.
This is the second such agreement
Neptune has secured through its wholly owned subsidiary 9354-7537 Quebec Inc.1
On Sept. 24, the Company announced it had entered into an agreement with the
British Columbia Liquor Distribution Branch (BCLDB), the wholesaler and public
retailer of non-medical cannabis products throughout that province.
"This is yet another landmark moment
in the cannabis movement, and will allow Neptune to bring the Mood Ring brand —
affordable, sustainable and premium cannabis products — to the millions of
people who live in that province," said Michael Cammarata, Chief Executive
Officer and President of Neptune.
Ontario is Canada's largest market
for adult-use cannabis products. The agreement authorizes Neptune to supply
Mood Ring products to the OCS for sale and wholesale distribution. The products
are anticipated to be available for purchase this fall through the OCS online
store.
Additionally, the Mood Ring product
line will be available to the 211 licensed private retailers in Ontario.
Together with British Columbia, this extends Neptune's reach to 515 retailers
in Canada.
The initial Mood Ring product
rollout will include quality High CBD Oil, High CBD Capsules, Classic Hashish,
and Legacy Hashish. Mood Ring uses Neptune's proprietary cold ethanol
extraction process technology to create full spectrum extracts for the
Company's CBD products and newly implemented solventless extraction for THC
concentrates.
Genome
British Columbia (Genome BC) congratulated two BC-led teams for their
projects designed to harness the power and potential of bio-innovation to
create healthier, more sustainable and prosperous communities.
The two projects, jointly valued at
over $10 million, bring together the best of Canadian applied science and
commercialization. The first project, CLEan
plAnt extractioN SEquencing Diagnostics (CLEANSED) for Clean Grapevines in
Canada, is being led by Sudarsana Poojari (Brock University) and Xuekui
Zhang (University of Victoria). Their end-user counterparts are Mike Rott
(Canadian Food Inspection Agency) and Bill Schenck (Canadian Grape
Certification Network). The team is working to develop a rapid, cost effective
genomic solution to replace the over 30 molecular and biological tests
currently performed on grapevines to look for disease. This one genomic test
will speed up the release of virus-free grapevine material from about three
years to one year or less, providing rapid access to valuable new varieties.
The Canadian Grapevine Certification Network will use this genomic test for
monitoring domestically bred vines, ensuring grape growers have faster and more
affordable access to clean vines to improve the health of their vineyards.
The second project, Fast-Track Breeding of Powdery
Mildew-Resistant Cannabis, is being led by Loren Rieseberg and Marco
Todesco (University of British Columbia) with industry partner Greg Baute
(Aurora Cannabis). This work will address a need to identify the desirable
breeding traits, including resistance to powdery mildew infection, that current
cannabis cultivars don't have. Genomic resources will be created that will
allow the project team to characterize sources of genetic resistance to powdery
mildew and begin to introduce them into Aurora's cannabis breeding program.
"It is an honour to invest in
this work and we congratulate all of the successful teams," said Dr.
Pascal Spothelfer, President and CEO, Genome BC. "We are realizing the
power of genomic science in both of these BC-led projects; for the grapevine
industry there is a huge unmet need for rapid disease testing and in the
cannabis industry we are supporting the important science behind this growing
industry."
Grapevine disease management has
been identified by the grape grower and wine industries as a top priority for
long–term sector sustainability. Estimated losses of over $23 million are
currently incurred annually by Canadian grape growers due to reduced yield of
infected grapes and increased fruit rejection by wineries. To replace the
currently infected acreage and meet ongoing renewal of vineyards the Canadian
industry needs access to 6.7 million domestically produced, virus free
vines/year. The grapevine project work will be implemented at the Canadian Food
Inspection Agency (CFIA) Sidney Centre for Plant Health (CPH). The proposed
methodology will reduce the cost of analysis, and time required, for industry
priority varieties imported into Canada, as well as the testing of certified
foreign sources destined for commercial planting.
Improved cannabis cultivars will
result in reduced losses to pathogen contamination and increase product
quality. The breeding pipeline itself
will also be used in the future to identify other important production and
high-value traits, and to create new cannabis cultivars with superior agronomic
performance.
These projects were part of an
announcement made yesterday by William Amos, Parliamentary Secretary (Science)
on behalf of the Minister of Innovation, Science and Industry Navdeep Bains.
They announced $16 million in federal support to 10 new genomics research
projects funded through Genome Canada. Provincial governments, businesses and
research partners are also investing nearly $41 million in co-funding, for a
total investment of $56.4 million in the areas of health, agriculture and the
environment.
Once again, today’s
podcast is sponsored by Cannabis Suisse Corp. (
OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's products are laboratory tested to
ensure the end users have access to a standardized, safe and consistent
product. Cannabis Suisse Corp. currently sells via a distribution network of
Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Investors can trade these stocks
and other ideas on our site using our list of
top stock trading apps including
Robinhood, Acorn, Stash and others.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Or www.potcasts.ca
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions.
Disclosure: Cannabis
Suisse Corp. (OTC: CSUI),is a paid featured company on
Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Learn more about sponsoring this podcast or be a guest
and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
